UP!
 |
|
| Traded as | NASDAQ: FMI |
|---|---|
| Headquarters | Cambridge, Massachusetts, United States |
|
Key people
|
|
| Products | FoundationOne FoundationOne Heme FoundationACT FoundationFocus CDxBRCA |
| Owners | Hoffmann-La Roche (56%, 2015) |
|
Number of employees
|
417 (March 2016) |
| Website | Official website |
Foundation Medicine, Inc. is a public American company based in Cambridge, Massachusetts which develops, manufactures and sells genomic analysis diagnostics for solid and circulating cancers. The company's tests are based on next-generation sequencing technology.
Foundation Medicine went public in August 2013; its stock is traded on the New York Stock Exchange under the symbol FMI. In 2015, revenue reached $93 million. As of March 2016, the company had 417 employees.
The company's flagship product was FoundationOne, followed by the FoundationOne Heme diagnostic test being for blood cancers.
In November and December 2014, the company established agreements with COTA (Cancer Outcomes Tracking and Analysis) and Flatiron Health, respectively, aimed at increasing the volume of genomic and clinical patient data available to it. In 2015, Roche announced a plan to purchase a 56.3% stake in the company through a US$780,000,000 purchase of newly issued shares. Roche also announced an intention to invest US$400,000,000 toward Foundation Medicine's operations, development and R&D activities.
Foundation Medicine also has business agreements with Johnson & Johnson and Novartis.
The company's chief executive officer (CEO) is Troy Cox. The company's chief operating officer (COO) is Steve Kafka. The company's chief commercial officer (CCO) is David Daly.
| 2016-05-04 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-03-09 | Reiterated Rating | BTIG Research | Neutral | |
| 2016-02-26 | Lower Price Target | Goldman Sachs | Neutral | $17.00 to $15.00 |
| 2016-02-26 | Lower Price Target | Goldman Sachs Group Inc. | Neutral | $17.00 to $15.00 |
| 2016-02-24 | Reiterated Rating | Leerink Swann | Market Perform | $27.00 to $15.00 |
| 2016-02-24 | Lower Price Target | JPMorgan Chase & Co. | Neutral | $23.00 to $20.00 |
| 2016-02-16 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-12-22 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-11-04 | Lower Price Target | Wedbush | Neutral | $26.00 to $19.00 |
| 2015-11-04 | Lower Price Target | JPMorgan Chase & Co. | Neutral | $25.00 to $23.00 |
| 2015-11-04 | Lower Price Target | Goldman Sachs | $29.00 to $25.00 | |
| 2015-11-04 | Lower Price Target | Leerink Swann | Market Perform | $36.00 to $27.00 |
| 2015-11-04 | Reiterated Rating | BTIG Research | Neutral | |
| 2015-10-15 | Reiterated Rating | BTIG Research | Buy | $30.00 |
| 2015-10-05 | Reiterated Rating | BTIG Research | Buy | $30.00 |
| 2015-09-18 | Reiterated Rating | Janney Montgomery Scott | Neutral | |
| 2015-09-17 | Reiterated Rating | Wedbush | Hold | $26.00 |
| 2015-09-16 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
| 2015-09-16 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2015-09-14 | Initiated Coverage | BTIG Research | Buy | $30.00 |
| 2015-07-30 | Downgrade | JMP Securities | Outperform to Market Perform | |
| 2015-05-14 | Reiterated Rating | Wedbush | Neutral | $45.00 to $41.00 |
| 2015-05-13 | Reiterated Rating | JMP Securities | Outperform | $67.00 to $57.00 |
| 2015-05-12 | Reiterated Rating | Goldman Sachs | Neutral | $55.00 to $47.00 |
| 2015-05-12 | Reiterated Rating | Leerink Swann | Market Perform | $50.00 to $46.00 |
| 2015-02-25 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $31.00 to $48.00 |
| 2015-02-25 | Downgrade | Wedbush | Outperform to Neutral | $45.00 |
| 2015-01-16 | Downgrade | Leerink Swann | Outperform to Market Perform | $30.00 to $50.00 |
| 2015-01-12 | Boost Price Target | Wedbush | Buy | $35.00 to $45.00 |
| 2014-12-19 | Initiated Coverage | Wells Fargo & Co. | Outperform | |
| 2014-12-19 | Initiated Coverage | Wells Fargo | Outperform | |
| 2014-10-17 | Upgrade | William Blair | Market Perform to Outperform | |
| 2014-08-01 | Initiated Coverage | Tigress Financial | Neutral to Neutral | |
| 2014-06-25 | Initiated Coverage | Janney Montgomery Scott | Neutral to Neutral | $28.00 |
| 2014-05-09 | Lower Price Target | Leerink Swann | $36.00 to $33.00 | |
| 2014-04-17 | Initiated Coverage | William Blair | Market Perform | |
| 2014-03-10 | Boost Price Target | JMP Securities | Outperform | $33.00 to $45.00 |
| 2014-03-04 | Initiated Coverage | Wedbush | Outperform | $50.00 |
| 2014-02-26 | Boost Price Target | Leerink Swann | $35.00 to $36.00 | |
| 2013-12-18 | Initiated Coverage | JMP Securities | Outperform | $33.00 |
| 2013-10-21 | Initiated Coverage | Sanford C. Bernstein | Market Perform | |
| 2013-10-21 | Initiated Coverage | Goldman Sachs | Neutral | |
| 2013-10-21 | Initiated Coverage | Leerink Swann | Outperform | |
| 2013-10-21 | Initiated Coverage | JPMorgan Chase & Co. | Neutral | $38.00 |
| 2016-05-04 | Reiterated Rating | Leerink Swann | Hold | |
| 2016-03-09 | Reiterated Rating | BTIG Research | Neutral | |
| 2016-02-26 | Lower Price Target | Goldman Sachs | Neutral | $17.00 to $15.00 |
| 2016-02-26 | Lower Price Target | Goldman Sachs Group Inc. | Neutral | $17.00 to $15.00 |
| 2016-02-24 | Reiterated Rating | Leerink Swann | Market Perform | $27.00 to $15.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In FMI 10 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Murphy Michael R | 1.57M |
| BlackRock Fund Advisors | 0.89M |
| Discovery Group I, LLC | 0.84M |
| BlackRock Institutional Trust Company, N.A. | 0.33M |
| SOUND ENERGY PARTNERS, INC. | 55000 |
| BlackRock Investment Management, LLC | 49423 |
| ROCKEFELLER FINANCIAL SERVICES INC | 10000 |
| BLACKROCK ADVISORS LLC | 7295 |
| BlackRock Group LTD | 4021 |
| Global X Management CO LLC | 475 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| ROCHE HOLDINGS INC See Footnote (1) | 72.91% (20604288) | FMI / |
| Google Ventures 2011, L.P. | 8.65% (2444653) | FMI / |
| Cox Troy Chief Executive Officer | 0.89% (252690) | FMI / |
| KRENITSKY KEVIN Chief Commercial Officer & SVP | 0.50% (140611) | ENZ / FMI / |
| Daly David Chief Commercial Officer | 0.41% (116261) | FMI / |
| Pellini Michael J President & CEO | 0.39% (110711) | FMI / |
| Hesslein Robert W. SVP and General Counsel | 0.38% (107723) | FMI / |
| Doherty Michael J Head of Product Development | 0.30% (83962) | FMI / |
| Borisy Alexis | 0.26% (73173) | FMI / |
| Miller Vincent A. Chief Medical Officer | 0.25% (70088) | FMI / |
| Nallicheri Melanie Chief Business Officer | 0.24% (68019) | FMI / |
| Ryan Jason Senior Vice President, Finance | 0.19% (52573) | FMI / |
| Kleiner Perkins Caufield & Byers XIV, LLC | 0.13% (37020) | FMI / |
| BYERS BROOK H | 0.13% (37020) | CDNA / FMI / PACB / VCYT / |
| Civik Thomas Chief Commercial Officer | 0.12% (33421) | FMI / |
| Kafka Steven J. Chief Operating Officer | 0.11% (31570) | FMI / |
| Fiedler Konstantin Chief Operating Officer | 0.10% (27829) | FMI / |
| DOUGHERTY MICHAEL R | 0.09% (24789) | BOTA / CEMP / CPXX / FMI / MRNS / TRVN / VPHM / |
| Schenkein David P | 0.08% (23326) | AGIO / BLUE / FMI / |
| JONES EVAN/ FA | 0.06% (17652) | CASM / FLDM / FMI / VCYT / |
| LEVIN MARK J | 0.06% (17462) | EBIO / FMI / |
| Yeshwant Krishna | 0.02% (5786) | FMI / |
UM